Chemoprevention of Oral Cancer

Risk Assessment, Plausible Intervention, and Monitoring
  • Jon Sudbø
  • Steinar Aamdal
  • Albrecht Reith
  • Asle Sudbø
Chapter
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Oral squamous cell carcinoma (OSCC) afflicts an estimated 500,000 patients annually worldwide (1,2). Oral carcinoma incidence is increasing in developing countries (1,3), substantially among younger people (4, 5, 6). Of note, patients with oral cavity cancer have an increased risk of acquiring a second primary cancer in other parts of the upper aerodigestive tract, such as the bronchial tree and esophagus (7).

Keywords

Oral Cancer Oral Squamous Cell Carcinoma Voronoi Diagram Aerodigestive Tract Premalignant Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pisani P, Parkin DM, Bray F, Ferlay J. Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18–29. Int J Cancer 1999;83:870–873.PubMedCrossRefGoogle Scholar
  2. 2.
    Silverman SJ, Gorsky M. Epidemiologic and demographic update in oral cancer: California and national data—1973 to 1985. J Am Dent Assoc 1990;120:495–499.PubMedGoogle Scholar
  3. 3.
    Lipkin A, Miller RH, Woodson GE. Squamous cell carcinoma of the oral cavity, pharynx, and larynx in young adults. Laryngoscope 1985;95:790–793.PubMedCrossRefGoogle Scholar
  4. 4.
    Macfarlane GJ, Boyle P, Scully C. Rising mortality from cancer of the tongue in young Scottish males. Lancet 1987;2:912.PubMedCrossRefGoogle Scholar
  5. 5.
    Macfarlane GJ, Boyle P, Evstifeeva TV, et al. Rising trends of oral cancer mortality among males worldwide: the return of an old public health problem. Cancer Causes Control 1994;5:259–265.PubMedCrossRefGoogle Scholar
  6. 6.
    Macfarlane GJ, Evstifeeva TV, Robertson C, et al. Trends of oral cancer mortality among females worldwide. Cancer Causes Control 1994;5:255–258.PubMedCrossRefGoogle Scholar
  7. 7.
    Kopelovich L, Henson DE, Gazdar AF, et al. Surrogate anatomic/functional sites for evaluating cancer risk: an extension of the field effect [editorial]. Clin Cancer Res 1999;5:3899–3905.PubMedGoogle Scholar
  8. 8.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8–31, 1.PubMedCrossRefGoogle Scholar
  9. 9.
    Shemen LJ, Klotz J, Schottenfeld D, Strong EW. Increase of tongue cancer in young men [letter]. JAMA 1984;252:1857.PubMedCrossRefGoogle Scholar
  10. 10.
    Friedlander PL, Schantz SP, Shaha AR, et al. Squamous cell carcinoma of the tongue in young patients: a matched-pair analysis. Head Neck 1998;20:363–368.PubMedCrossRefGoogle Scholar
  11. 11.
    Callery CD, Spiro RH, Strong EW. Changing trends in the management of squamous carcinoma of the tongue. Am J Surg 1984;148:449–454.PubMedCrossRefGoogle Scholar
  12. 12.
    de Vries N, van Zandwijk N, Pastorino U. Chemoprevention in the management of oral cancer: EUROSCAN and other studies. Eur J Cancer B Oral Oncol 1992;28B:153–157.PubMedGoogle Scholar
  13. 13.
    Kelloff GJ, Boone CW, Steele VK, et al. Development of chemopreventive agents for lung and upper aerodigestive tract cancers. J Cell Biochem Suppl 1993;17F:2–17.PubMedGoogle Scholar
  14. 14.
    Schantz SP, Ostroff JS. Novel approaches to the prevention of head and neck cancer. Proc Soc Exp Biol Med 1997;216: 275–282.PubMedGoogle Scholar
  15. 15.
    Kelloff GJ, Sigman CC, Greenwald P. Cancer chemoprevention: progress and promise. Eur J Cancer 1999;35:1755–1762.PubMedCrossRefGoogle Scholar
  16. 16.
    Kelloff GJ, Crowell JA, Steele VE, et al. Progress in cancer chemoprevention. Ann NY Acad Sci 1999;889:1–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7–33.PubMedCrossRefGoogle Scholar
  18. 18.
    Licciardello JT, Spitx MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: Second cancer of the head and neck, oesophagus and lung. Int J Radiat Oncol Biol Phys 1989;17:467–476.PubMedGoogle Scholar
  19. 19.
    Hays GL, Lippman SM, Flaitz CM, et al. Co-carcinogenesis and field cancerization: oral lesions offer first signs. J Am Dent Assoc 1995;126:47–51.PubMedGoogle Scholar
  20. 20.
    Scholes AG, Woolgar JA, Boyle MA, et al. Synchronous oral carcinomas: independent or common clonal origin? Cancer Res 1998;58:2003–2006.PubMedGoogle Scholar
  21. 21.
    Califano J, Westra WH, Meininger G, et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 2000;6:347–352.PubMedGoogle Scholar
  22. 22.
    Bishop JM. The molecular genetics of cancer. Science 1987;235:305–311.PubMedCrossRefGoogle Scholar
  23. 23.
    Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989;17:449–456.PubMedGoogle Scholar
  24. 24.
    Weber RG, Scheer M, Born IA, et al. Recurrent chromosomal imbalances detected in biopsy material from oral premalignant and malignant lesions by combined tissue microdissection, universal DNA amplification, and comparative genomic hybridization. Am J Pathol 1998;153:295–303.PubMedGoogle Scholar
  25. 25.
    Sudbϕ J, Kildal W, Johannessen AC, et al. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol 2002;20:456–462.CrossRefGoogle Scholar
  26. 26.
    Sudbϕ J, Kildal W, Risberg B, et al. DNA content as a prognostic marker in patients with oral leukoplakias. N Engl J Med 2001;344:1270–1278.CrossRefGoogle Scholar
  27. 27.
    Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer 1975;36:1386–1392.PubMedCrossRefGoogle Scholar
  28. 28.
    Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg Oral Med Oral Pathol 1986;61: 373–381.PubMedCrossRefGoogle Scholar
  29. 29.
    Silverman SJ, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53:563–568.PubMedCrossRefGoogle Scholar
  30. 30.
    Silverman SJ, Gorsky M. Epidemiologic and demographic update in oral cancer: California and national data—1973 to 1985. J Am Dent Assoc 1990;120:495–499.PubMedGoogle Scholar
  31. 31.
    Brunin F, Mosseri V, Jaulerry C, et al. Cancer of the base of the tongue: past and future. Head Neck 1999;21:751–759.PubMedCrossRefGoogle Scholar
  32. 32.
    Wight AJ, Ogden GR. Possible mechanisms by which alcohol may influence the development of oral cancer—a review. Oral Oncol 1998;34:441–447.PubMedCrossRefGoogle Scholar
  33. 33.
    Ogden GR, Wight AJ. Aetiology of oral cancer: alcohol. Br J Oral Maxillofac Surg 1998;36:247–251.PubMedCrossRefGoogle Scholar
  34. 34.
    Schantz SP, Zhang ZF, Spitz MS, et al. Genetic susceptibility to head and neck cancer: interaction between nutrition and mutagen sensitivity. Laryngoscope 1997;107:765–781.PubMedCrossRefGoogle Scholar
  35. 35.
    Cloos J, Spitz MR, Schantz SP, et al. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:530–535.PubMedCrossRefGoogle Scholar
  36. 36.
    Schantz SP, Spitz MR, Hsu TC. Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst 1990;82:1773–1775.PubMedCrossRefGoogle Scholar
  37. 37.
    Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland [see comments]. N Engl J Med 2000;343:78–85.PubMedCrossRefGoogle Scholar
  38. 38.
    Hoover RN. Cancer—nature, nurture, or both [editorial; comment]. N Engl J Med 2000;343:135–136.PubMedCrossRefGoogle Scholar
  39. 39.
    Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985;313:793–799.PubMedGoogle Scholar
  40. 40.
    Kayser K, Schlegel W. Pattern recognition in histo-pathology: basic considerations. Methods Inf Med 1982;21:15–22.PubMedGoogle Scholar
  41. 41.
    Sudbϕ J, Bryne M, Johannessen A, Reith A. Comparison of histological grading and large scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia. J Pathol 2001; 194:946–955.Google Scholar
  42. 42.
    Heppner GH. Cancer cell societies and tumor progression. Stem Cells 1993;11:199–203.PubMedCrossRefGoogle Scholar
  43. 43.
    Warnakulasuriya S. Lack of molecular markers to predict malignant potential of oral precancer [editorial; comment]. J Pathol 2000;190:407–409.PubMedCrossRefGoogle Scholar
  44. 44.
    Karabulut A, Reibel J, Therkildsen MH, et al. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med 1995;24:198–200.PubMedCrossRefGoogle Scholar
  45. 45.
    Sudbϕ J, Bryne M, Johannessen AC, et al. Comparison of histological grading and large scale genomic status (DNA ploidy) as prognostic tools in oral dysplasia. J Pathol 2001;194:303–310.CrossRefGoogle Scholar
  46. 46.
    Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702–1710.PubMedGoogle Scholar
  47. 47.
    Sudbϕ J, Ried T, Bryne M, et al. Abnormal DNA content predicts the occurence of carcinomas in non-dysplastic oral white patches. Oral Oncol 2001;37:558–565.CrossRefGoogle Scholar
  48. 48.
    Califano J, Westra WH, Koch W, et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. J Natl Cancer Inst 1999;91:599–604.PubMedCrossRefGoogle Scholar
  49. 49.
    Boveri T. Zur Frage der Entstehung maligner Tumoren. Gustav Fischer, Jena, 1914.Google Scholar
  50. 50.
    Saunders WS, Shuster M, Huang X, et al. Chromosomal instability and cytoskeletal defects in oral cancer cells. Proc Natl Acad Sci USA 2000;97:303–308.PubMedCrossRefGoogle Scholar
  51. 51.
    Gardner RD, Burke DJ. The spindle checkpoint: two transitions, two pathways. Trends Cell Biol 2000;10:154–158.PubMedCrossRefGoogle Scholar
  52. 52.
    Ried T, Heselmeyer-Haddad K, Blegen H, et al. Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 1999;25:195–204.PubMedCrossRefGoogle Scholar
  53. 53.
    Cahill DP, da Costa LT, Carson-Walter EB, et al. Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics 1999;58:181–187.PubMedCrossRefGoogle Scholar
  54. 54.
    Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643–649.PubMedCrossRefGoogle Scholar
  55. 55.
    Ghadimi BM, Sackett DL, Difilippantonio MJ, et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosom Cancer 2000;27:183–190.PubMedCrossRefGoogle Scholar
  56. 56.
    Seoane J, Asenjo JA, Bascones A, et al. Flow cytometric DNA ploidy analysis of oral cancer comparison with histologic grading. Oral Oncol 1999;35:266–272.PubMedCrossRefGoogle Scholar
  57. 57.
    Hogmo A, Munck-Wikland E, Kuylenstierna R, et al. Nuclear DNA content and p53 immunostaining in metachronous preneoplastic lesions and subsequent carcinomas of the oral cavity. Head Neck 1996;18:433–440.PubMedCrossRefGoogle Scholar
  58. 58.
    Abdel-Salam M, Mayall BH, Chew K, Silverman S. Which oral white lesions will become malignant? An image cytometric study. Oral Surg Oral Med Oral Pathol 1990;69: 345–350.PubMedCrossRefGoogle Scholar
  59. 59.
    Abdel-Salam M, Mayall BH, Chew K, et al. Prediction of malignant transformation in oral epithelial lesions by image cytometry. Cancer 1988;62:1981–1987.PubMedCrossRefGoogle Scholar
  60. 60.
    Bocking A, Giroud F, Reith A. Consensus report of the ESACP task force on standardization of diagnostic DNA image cytometry. European Society for Analytical Cellular Pathology. Anal Cell Pathol 1995;8:67–74.PubMedGoogle Scholar
  61. 61.
    Giroud F, Haroske G, Reith A, Bocking A. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part II: Specific recommendations for quality assurance. European Society for Analytical Cellular Pathology. Anal Cell Pathol 1998;17:201–208.PubMedGoogle Scholar
  62. 62.
    Haroske G, Giroud F, Reith A, Bocking A. 1997 ESACP consensus report on diagnostic DNA image cytometry. Part I: basic considerations and recommendations for preparation, measurement and interpretation. European Society for Analytical Cellular Pathology. Anal Cell Pathol 1998;17: 189–200.PubMedGoogle Scholar
  63. 63.
    Haroske G, Baak JP, Danielsen H, et al. Fourth updated ESACP consensus report on diagnostic DNA image cytometry. Anal Cell Pathol 2001;23:89–95.PubMedGoogle Scholar
  64. 64.
    Sudbϕ J, Kildal W, Johannessen AC, et al. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J Clin Oncol 2002;20:456–462.CrossRefGoogle Scholar
  65. 65.
    Sudbϕ J. Pathology in disgrace? J Pathol 2002;196:244–245.CrossRefGoogle Scholar
  66. 66.
    Bouquot JE. Oral leukoplakia and erythroplakia: a review and update. Pract Periodontics Aesthet Dent 1994;6:9–17.PubMedGoogle Scholar
  67. 67.
    Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000;12: 82–88.PubMedCrossRefGoogle Scholar
  68. 68.
    Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995;332: 1405–1410.PubMedCrossRefGoogle Scholar
  69. 69.
    Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys 1989;17:691–614.PubMedGoogle Scholar
  70. 70.
    Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993;328:184–194.PubMedCrossRefGoogle Scholar
  71. 71.
    Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953;6:963–968.PubMedCrossRefGoogle Scholar
  72. 72.
    van Oijen MG, Slootweg PJ. Oral field cancerization: carcinogen-induced independent events or micrometastatic deposits? Cancer Epidemiol Biomarkers Prev 2000;9:249–256.PubMedGoogle Scholar
  73. 73.
    Zeng Q, Smith DC, Suscovich TJ, et al. Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole. Clin Cancer Res 2000;6:2245–2251.PubMedGoogle Scholar
  74. 74.
    Michel LS, Liberal V, Chatterjee A, et al. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 2001;409:355–359.PubMedCrossRefGoogle Scholar
  75. 75.
    Gupta PC, Mehta FS, Pindborg JJ, et al. Intervention study for primary prevention of oral cancer among 36,000 Indian tobacco users. Lancet 1986;1:1235–1239.PubMedCrossRefGoogle Scholar
  76. 76.
    Lippman SM, Hong WK. Molecular markers of the risk of oral cancer [editorial]. N Engl J Med 2001;344:1323–1326.PubMedCrossRefGoogle Scholar
  77. 77.
    Li M, Wu X, Xu XC. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. Int J Cancer 2001; 93:218–223.PubMedCrossRefGoogle Scholar
  78. 78.
    Chen WS, Wei SJ, Liu JM, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001;91: 894–899.PubMedCrossRefGoogle Scholar
  79. 79.
    Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;90:1609–1620.PubMedCrossRefGoogle Scholar
  80. 80.
    van Rees BP, Ristimaki A. Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand J Gastroenterol 2001; 36:897–903.PubMedCrossRefGoogle Scholar
  81. 81.
    Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908–7916.PubMedCrossRefGoogle Scholar
  82. 82.
    Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.PubMedCrossRefGoogle Scholar
  83. 83.
    Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315: 1501–1505.PubMedGoogle Scholar
  84. 84.
    Sudbϕ J, Marcelpoil R, Reith A. New algorithms based on the Voronoi Diagram applied in a pilot study on normal mucosa and carcinomas. Anal Cell Pathol 2000;21:71–86.Google Scholar
  85. 85.
    Sudbϕ J, Bankfalvi A, Bryne M, et al. Prognostic value of graph theory-based tissue architecture analysis in carcinomas of the tongue. Lab Invest 2000;80:1881–1889.CrossRefGoogle Scholar
  86. 86.
    Sudbϕ J, Marcelpoil R, Reith A. Caveats: numerical requirements in graph theory based quantitation of tissue architecture. Anal Cell Pathol 2000;21:59–69.Google Scholar
  87. 87.
    Chaikin PM, Lubensky TC. Principles of Condensed Matter Physics. Cambridge University Press, Cambridge; 1995.Google Scholar
  88. 88.
    Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991–994.PubMedGoogle Scholar
  89. 89.
    Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276–1280.PubMedGoogle Scholar
  90. 90.
    Ristimaki A, Nieminen O, Saukkonen K, et al. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 2001;158:849–853.PubMedGoogle Scholar
  91. 91.
    Zimmermann KC, Sarbia M, Weber AA, et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59:198–204.PubMedGoogle Scholar
  92. 92.
    Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated adenocarcinomas. Cancer Res 1998;58:2929–2934.PubMedGoogle Scholar
  93. 93.
    Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107: 1183–1188.PubMedGoogle Scholar
  94. 94.
    Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544–551.PubMedCrossRefGoogle Scholar
  95. 95.
    Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001;276:18,563–18,569.PubMedCrossRefGoogle Scholar
  96. 96.
    Inoue H, Yokoyama C, Hara S, et al. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem 1995;270:24,965–24,971.PubMedCrossRefGoogle Scholar
  97. 97.
    Sheng H, Shao J, Dixon DA, et al. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000;275:6628–6635.PubMedCrossRefGoogle Scholar
  98. 98.
    Bartsch H. Studies on biomarkers in cancer etiology and prevention: a summary and challenge of 20 years of interdisciplinary research. Mutat Res 2000;462:255–279.PubMedCrossRefGoogle Scholar
  99. 99.
    Nair J, Barbin A, Velic I, Bartsch H. Etheno DNA-base adducts from endogenous reactive species. Mutat Res 1999; 424:59–69.PubMedGoogle Scholar
  100. 100.
    Bartsch H, Nair J. Ultrasensitive and specific detection methods for exocylic DNA adducts: markers for lipid peroxidation and oxidative stress. Toxicology 2000;153: 105–114.PubMedCrossRefGoogle Scholar
  101. 101.
    Bartsch H, Nair J. Exocyclic DNA adducts as secondary markers for oxidative stress: applications in human cancer etiology and risk assessment. Adv Exp Med Biol 2001;500: 675–686.PubMedGoogle Scholar
  102. 102.
    Schmezer P, Rupprecht T, Tisch M, et al. Laryngeal mucosa of head and neck cancer patients shows increased DNA damage as detected by single cell microgel electrophoresis. Toxicology 2000;144:149–154.PubMedCrossRefGoogle Scholar
  103. 103.
    Oberley TD. Oxidative damage and cancer. Am J Pathol 2002;160:403–408.PubMedGoogle Scholar
  104. 104.
    Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.PubMedCrossRefGoogle Scholar
  105. 105.
    Giardiello FM, Yang WK, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054–1059.PubMedCrossRefGoogle Scholar
  106. 106.
    Chau I, Cunningham D. Cyxlooxygenase inhibition in cancer—a blind alley or a new therapeutic reality? N Engl J Med 2002;346:1085–1086.PubMedCrossRefGoogle Scholar
  107. 107.
    Song X, Lin P-O, Johnson AL, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;94:585–591.PubMedGoogle Scholar
  108. 108.
    Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer prevention. Lancet Oncol 2002;3: 166–174.PubMedCrossRefGoogle Scholar
  109. 109.
    Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024–1028.PubMedCrossRefGoogle Scholar
  110. 110.
    Chakravarti N, Mathur M, Bahadur S, et al. Expression of RARalpha and RARbeta in human oral potentially malignant and neoplastic lesions. Int J Cancer 2001;91:27–31.PubMedCrossRefGoogle Scholar
  111. 111.
    Lippman SM, Heyman RA, Kurie JM, et al. Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem Suppl 1995;22:1–10.PubMedCrossRefGoogle Scholar
  112. 112.
    Lippman SM, Spitz MR, Huber MH, Hong WK. Strategies for chemoprevention study of premalignancy and second primary tumors in the head and neck. Curr Opin Oncol 1995;7: 234–241.PubMedCrossRefGoogle Scholar
  113. 113.
    Mestre JR, Subbaramaiah K, Sacks PG, et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997;57:2890–2895.PubMedGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Jon Sudbø
    • 1
    • 2
  • Steinar Aamdal
    • 3
  • Albrecht Reith
    • 4
  • Asle Sudbø
    • 5
  1. 1.Department of Medical OncologyNorwegian Radium HospitalOslo
  2. 2.Department of RadiotherapyNorwegian Radium HospitalOsloNorway
  3. 3.Department of Clinical Cancer ResearchNorwegian Radium HospitalOsloNorway
  4. 4.Department of PathologyNorwegian Radium HospitalOsloNorway
  5. 5.Department of PhysicsNorwegian University of Science and TechnologyTrondheimNorway

Personalised recommendations